None listed
Conditions
Interventions
Drug : Subjects continues treatment with Lazertinib during the trial period until disease progression or unacceptable toxicity. From Visit 1 (the first day of administration of Lazertinib), a total of
Sponsors
Konkuk University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Provide signed and dated written consent prior to examination-specific procedures 2) Male and female adults 19 years of age or older 3) Patients with histologically or cytologically diagnosed non-small cell lung cancer (NSCLC) and at the time of enrollment locally advanced or metastatic inoperable (ie, stages IIIB to IV not suitable for definitive CCRT) or recurrent patients 4) Patients with positive EGFR mutations (L858R, E19del, L861Q, G719X) at the time of diagnosis However, in addition to the EGFR mutation, it is also possible to enroll a case accompanied by de novo T790M. 5) Patients who have previously received EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib) and have confirmed disease progression (PD) • Regardless of the order of cytotoxic chemotherapy and EGFR-TKIs treatment in previous chemotherapy • At least one of the EGFR-TKIs must be used, regardless of the presence or absence of cytotoxic chemotherapy 6) Patients who can sufficiently collect BALiquid through bronchoscopy immediately before participating in this study after treatment with EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib) 7) Patients with positive T790M mutation in lung lavage fluid (BALiquid) by PANAmutyper assay 8) ECOG performance status 0~2 9) If the predicted survival period is more than 12 weeks 10) At least 1 measurable lesion (excluding brain) according to RECIST V1.1 11) Adequate bone marrow reserve or organ function in all of the following cases: • Absolute neutrophil count (ANC) = 1.5 x 109/L • Platelet count = 100 x 109/L • Hemoglobin = 9.0 g/dL • Alanine aminotransferase (ALT) = 2.5 times the upper limit of normal (ULN) if liver metastases cannot be demonstrated, or = 5x ULN if liver metastases are present • Aspartate aminotransferase (AST) = 2.5x ULN if liver metastases cannot be demonstrated, or = 5x ULN if liver metastases are present • Total bilirubin = 1.5x ULN in the absence of liver metastases, or = 3x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases • Serum creatinine = 1.5x ULN However, if the creatinine is > 1.5x ULN, registration is possible if the creatinine clearance measured by the general method of the testing institution (eg, Cockcroft and Gault equation) is = 50 ml/min. 12) Patients who agreed to use effective contraception during the clinical trial period Women of childbearing potential (less than 1 year since the last menstrual period as of the date of consent) or male patients must be willing to use an effective method of contraception for at least 3 months after completion of Lazertinib administration must tell the truth.
Exclusion criteria
Exclusion criteria: 1) Patients who have previously taken or are currently taking other drugs targeting the T790M positive mutation 2) Patients who have taken strong cytochrome P450 (CYP) 3A4 inhibitors or inducers prior to at least 1 week of taking Lazertinib 3) All malignancies other than previous or coexisting lung cancer However, non-melanomatous skin cancer, cervical carcinoma in situ, ductal carcinoma in situ, thyroid cancer, or malignant tumors that have been effectively treated for more than 3 years and are considered to be cured are excluded. 4) History of symptomatic requiring aggressive treatment chronic heart failure or serious cardiac arrhythmias 5) History of myocardial infarction or unstable angina prior to 24 weeks of study enrollment 6) Patients with clinically significant QTcB correction value > 480 msec on 12-lead ECG 7) History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid treatment, or evidence of clinically active ILD 8) refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing the product, or past significant bowel resection that may interfere with the proper absorption of Lazertinib 9) History of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 10) Known active hepatitis B infection (defined as presence of HBsAg and/or HBV DNA), known active hepatitis C infection (defined as presence of HCV RNA) and/or known HIV carriers 11) Women who are pregnant or lactating, or who have a positive pregnancy test before registration in the clinical trial 12) Patients with severe hypersensitivity to the main ingredient or excipient of the test drug (lasertinib) 13) Patients with untreated active central nervous system (CNS) metastases confirmed by screening and prior CT or MRI evaluation However, registration is possible in the following cases. - Imaging and neurological stability after stopping the administration of corticosteroids and anticonvulsants for at least 2 weeks before enrollment after treatment for active central nervous system (CNS) metastases - Patients with asymptomatic CNS metastases 14) uncontrolled infectious disease However, infectious diseases that require parenteral antibiotic administration are excluded, but participation is possible after the infection is completely eliminated or controlled. 15) Patients who are unable to participate in the clinical trial at the discretion of the investigator, such as when it is difficult to comply with the procedures, restrictions, and requirements of the clinical trial protocol, or follow-up management 16) Patients who have administered other investigational drugs within 30 days prior to test administration However, cases where gefitinib, erlotinib, afatinib, or dacomitinib are taken as clinical investigational drugs are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate(ORR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate(DCR);Progression-free survival(PFS);Next-generation sequencing (NGS) is performed using the lung lavage remaining after T790M analysis to analyze whether there are differences in the predictive response to Lazertinib and progression-free survival (PFS) in indicators such as mutations type, frequency of mutations and tumor mutation burden (TMB).;Adverse events due to Lasertinib administration should be evaluated according to NCI-CTCAE V5.0. For vital signs, physical examination, and clinically significant laboratory results collected during the study, toxicity should be evaluated according to the NCI-CTCAE V5.0 | — |
Countries
Korea, Republic of
Contacts
Public ContactKye Young Lee
Konkuk University Medical Center
Outcome results
None listed